Steven Schulman, M.D. attended the Johns Hopkins University School of Medicine in 1981. He fulfilled his training in internal medicine and chief residency, as well as completing his cardiology fellowship at Hopkins. Dr. Schulman joined the faculty in 1988 and became director of the Coronary Care Unit (CCU) in 1992, where he led several clinical trials looking to improve care in patients with acute myocardial infarction. Dr. Schulman currently attends in the CCU 4 months a year, admitting over 100 patients a month and treating them for advanced cardiovascular care. He has won numerous teaching awards from Hopkins residents and fellows over the years. While attending in the CCU, Dr. Schulman teaches and guides the next generation of residents and fellows about acute cardiac care. Additionally, over the last three years Dr. Schulman has run the fellowship selection process for cardiology fellows. In July 2012, Dr. Schulman will become the new Cardiology Fellowship Program Director at Johns Hopkins.
Dr. Schulmans current efforts include his work in the area of acute myocardial infarction (heart attacks). An important concept in the genesis of acute myocardial infarction is that blood needs to clot on top of the ruptured plaque. The current standard therapy for patients with acute myocardial infarction is to restore coronary blood flow with percutaneous coronary intervention, also known as angioplasty and stenting. With innovative technology, called RNA microarray, approximately 35,000 genes associated with inflammation and other diseases can be examined. This specialized technology is utilized to determine whether patients with acute myocardial infarction express different genes than patients with stable vascular disease. Dr. Schulman and his team are on the cusp of being able to identify: what differs in the clot that causes acute myocardial infarctions, genetic factors that may predict which patients respond to standard therapies, and who is at increased risk of a second heart attack as they dont respond to standard therapies. These data will advance their understanding of why acute myocardial infarctions occur, and may result in new therapies for the large percent of patients who do not respond to typical blood thinning agents.